G3335 Acetate 被发现是一种新型 PPARgamma 拮抗剂。

G3335 Acetate was discovered to be a novel PPARgamma antagonist.

G3335 exhibits a highly specific binding affinity against PPARgamma (K(D) = 8.34 microM) and is able to block rosiglitazone, a potent PPARgamma agonist, in the stimulation of the interaction between the PPARgamma ligand-binding domain (LBD) and RXRalpha-LBD. Yeast two-hybrid assays demonstrated that G3335 exhibits strong antagonistic activity (IC50 = 8.67 microM) in perturbing rosiglitazone in the promotion of the PPARgamma-LBD-CBP interaction.

T21598L

C18H23N3O7

393.39

G3335 Acetate (36099-95-3 free base);G3335 Acetate

DMSO:55 mg/ml (139.81 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years